| Identification | Back Directory | [Name]
BMS-962212
(BMS962212) | [CAS]
1430114-34-3 | [Synonyms]
BMS-962212
(BMS962212)
(S,E)-4-(2-(3-(3-Chloro-2-fluoro-6-(1H-tetrazol-1- yl)phenyl)acryloyl)-5-(4-methyl-2-oxopiperazin-1-yl)- 1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid
Benzoic acid, 4-[[[(1S)-2-[(2E)-3-[3-chloro-2-fluoro-6-(1H-tetrazol-1-yl)phenyl]-1-oxo-2-propen-1-yl]-1,2,3,4-tetrahydro-5-(4-methyl-2-oxo-1-piperazinyl)-1-isoquinolinyl]carbonyl]amino]- | [Molecular Formula]
C32H28ClFN8O5 | [MDL Number]
MFCD32196610 | [MOL File]
1430114-34-3.mol | [Molecular Weight]
659.07 |
| Chemical Properties | Back Directory | [density ]
1.51±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
4.27±0.10(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
BMS-962212 is a direct, reversible, selective factor XIa (FXIa) inhibitor . BMS-962212 is well tolerated, with fast onset of pharmacodynamic (PD) responses and rapid elimination. BMS-962212 increases exposure dependently in activated partial thromboplastin time, and decreases exposure dependently in FXI clotting activity[1]. | [storage]
Store at -20°C | [References]
[1] Perera V, et al. First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects. Br J Clin Pharmacol. 2018 May;84(5):8 DOI:10.1111/bcp.13520 |
|
| Company Name: |
Wuhan Topule
|
| Tel: |
+86-02787215551 +86-19945035818 |
| Website: |
http://www.topule.com/ |
|